Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma

References

• Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010 Oct;21(Suppl 7):vii252–vii261.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116–1127.
   PubMed Web of Science ®Google Scholar
• Licitra L, Mesia R, Rivera F, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011 May;22(5):1078–1087.
   PubMed Web of Science ®Google Scholar
• Licitra L, Storkel S, Kerr KM, et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013 Apr;49(6):1161–1168.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Psyrri A, Mesia R, et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol. 2014 Apr;25(4):801–807.
   PubMed Web of Science ®Google Scholar
• Mesia R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2010 Oct;21(10):1967–1973.
   PubMed Web of Science ®Google Scholar
• https://www.journalslibrary.nihr.ac.uk/hta/hta13Suppl308/#/abstract accessed 2018 Apr 26
   Google Scholar
• Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005 Dec 1;23(34):8646–8654.
   PubMed Web of Science ®Google Scholar
• Guo Y, Shi M, Yang A, et al. Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of an open-label, single-arm, multicenter trial. Head Neck. 2015 Aug;37(8):1081–1087.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Hasegawa Y, Takahashi S, et al. Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial. Jpn J Clin Oncol. 2013 May;43(5):524–531.
   PubMed Web of Science ®Google Scholar
• Hitt R, Irigoyen A, Cortes-Funes H, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012 Apr;23(4):1016–1022.
   PubMed Web of Science ®Google Scholar
• Guigay J, Fayette J, Dillies AF, et al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann Oncol. 2015 Sept;26(9):1941–1947.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Licitra L, Stohlmacher-Williams J, et al. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2013 Sep;49(13):2877–2883.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Stohlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013 Jul;14(8):697–710.
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Dakhil S, Kornek G, et al. PARTNER: an open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2016;61:31–40.
   PubMed Web of Science ®Google Scholar
• Del Barco ME, Mesia R, Adansa Klain JC, et al. Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancerTTCC-2009-03/VECTITAX study. Oral Oncol. 2016;62:54–59.
   PubMed Web of Science ®Google Scholar
• Weiss JM, Bagley S, Hwang WT, et al. Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer. 2016 Aug 1;122(15):2350–2355.
   PubMed Web of Science ®Google Scholar
• Argiris A, Li S, Savvides P, et al. Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial. J Clin Oncol. 2017;35((suppl)[15]):6000 (abstract).
   Google Scholar
• Vermorken JB, Peyrade F, Krauss J, et al. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Ann Oncol. 2014 Mar;25(3):682–688.
   PubMed Web of Science ®Google Scholar
• Abdul Razak AR, Soulieres D, Laurie SA, et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol. 2013 Mar;24(3):761–769.
   PubMed Web of Science ®Google Scholar
• Jimeno A, Machiels JP, Wirth L, et al. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer. 2016 Dec 15;122(24):3803–3811.
   PubMed Web of Science ®Google Scholar
• Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011 Mar 20;29(9):1140–1145.
   PubMed Web of Science ®Google Scholar
• Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: southwest Oncology Group Study S0420. J Clin Oncol. 2010 Jul 10;28(20):3330–3335.
   PubMed Web of Science ®Google Scholar
• Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol. 1985;15(3):283–289.
   PubMed Web of Science ®Google Scholar
• A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum +. 5-FU in end stage squamous carcinoma of the head and neck liverpool head and neck oncology group. Br J Cancer. 1990 Feb;61(2):311–315.
   PubMedGoogle Scholar
• Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer. 2004 Sep;40(14):2071–2076.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Meyers F, Hendrickson C, et al. A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck A Northern California oncology group study. Cancer. 1983 Nov 1;52(9):1563–1569.
   PubMed Web of Science ®Google Scholar
• Paccagnella A, Pappagallo GL, Segati R, et al. Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer A GSTTC randomised phase II study. Eur J Cancer. 1993;29A(5):704–708.
   PubMed Web of Science ®Google Scholar
• Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck A phase III study of the EORTC head and neck cancer cooperative group. Ann Oncol. 1994 Jul;5(6):521–526.
   PubMed Web of Science ®Google Scholar
• Vogl SE, Schoenfeld DA, Kaplan BH, et al. A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer. 1985 Aug 1;56(3):432–442.
   PubMed Web of Science ®Google Scholar
• Schrijvers D, Johnson J, Jiminez U, et al. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer head and neck interferon cooperative study group. J Clin Oncol. 1998 Mar;16(3):1054–1059.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992 Feb;10(2):257–263.
   PubMed Web of Science ®Google Scholar
• Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern cooperative oncology group. J Clin Oncol. 2005 May 20;23(15):3562–3567.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: eastern cooperative oncology group study E1393. J Clin Oncol. 2001 Feb 15;19(4):1088–1095.
   PubMed Web of Science ®Google Scholar
• Ferrari D, Fiore J, Codeca C, et al. A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer. Anticancer Drugs. 2009 Mar;20(3):185–190.
   PubMed Web of Science ®Google Scholar
• Caponigro F, Comella P, Rivellini F, et al. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern italy cooperative oncology group (SICOG). Ann Oncol. 2000 May;11(5):575–580.
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Papakostas P, Dafni U, et al. Paclitaxel and gemcitabine vs paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the hellenic cooperative oncology group. Ann Oncol. 2006 Oct;17(10):1560–1567.
   PubMed Web of Science ®Google Scholar
• Urba S, Van Herpen CM, Sahoo TP, et al. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. Cancer. 2012 Oct 1;118(19):4694–4705.
   PubMed Web of Science ®Google Scholar
• Urba S, Gatz J, Shen W, et al. Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy. Oral Oncol. 2012 Aug;48(8):723–729.
   PubMed Web of Science ®Google Scholar
• Chang PM, Tzeng CH, Chen MH, et al. Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. Cancer Chemother Pharmacol. 2011 Dec;68(6):1477–1484.
   PubMed Web of Science ®Google Scholar
• Guntinas-Lichius O, Appenrodt S, Veelken F, et al. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope. 2006 Apr;116(4):613–618.
   PubMed Web of Science ®Google Scholar
• Won YW, Park YH, Ahn MJ, et al. A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Feb;22(2):417–423.
   PubMed Web of Science ®Google Scholar
• Arnold SM, Moon J, Williamson SK, et al. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: southwest Oncology Group trial S0618. Invest New Drugs. 2011 Apr;29(2):352–359.
   PubMed Web of Science ®Google Scholar
• Fujii M, Tomita K, Nishijima W, et al. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer. Jpn J Clin Oncol. 2010 Mar;40(3):214–221.
   PubMed Web of Science ®Google Scholar
• Yang MH, Chang PM, Tzeng CH, et al. Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study. Cancer Chemother Pharmacol. 2010 Jan;65(2):259–265.
   PubMed Web of Science ®Google Scholar
• Patil VM, Noronha V, Joshi A, et al. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol. 2015 Mar;51(3):279–286.
   PubMed Web of Science ®Google Scholar
• Tortochaux J, Tao Y, Tournay E, et al. Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent. Radiother Oncol. 2011 Jul;100(1):70–75.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 Nov 10;375(19):1856–1867.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Blumenschein GR Jr., Fayette J, et al. Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): outcomes in first-line (1L) R/m patients and updated safety and efficacy. J Clin Oncol. 2017;35(suppl):-6019 (abstract).
   Google Scholar
• Ferris RL, Licitra L, Fayette J, et al. Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): efficacy and safety in CheckMate 141 by prior cetuximab use. J Clin Oncol. 2017;35(suppl):-6020 (abstract).
   PubMedGoogle Scholar
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125554s024lbl.pdf accessed Apr 26, 2018
   Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf accessed Apr 26, 2018.
   Google Scholar
• https://www.nice.org.uk/guidance/ta490/documents/final-appraisal-determination-document accessed 2018 Apr 26
   Google Scholar
• Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase ii study. J Clin Oncol. 2017 May 10;35(14):1542–1549.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016 Jul;17(7):956–965.
   PubMed Web of Science ®Google Scholar
• Chow LQ, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016 Nov 10;34(32):3838–3845.
   Google Scholar
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s015lbl.pdf accessed Apr 26, 2018. 2017.
   Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003820/WC500190990.pdf accessed Apr 26, 2018.
   Google Scholar
• Cohen EE, Harrington K, Le Tourneau C, et al. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase 3 KEYNOTE-040 trial. Ann.Oncol. 2017;28(suppl 5):LBA45_PR (abstract).
   Google Scholar
• Zandberg DP, Rollins S, Goloubeva O, et al. A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol Immunother. 2015 Mar;64(3):367–379.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Van Maanen A, Vandenbulcke JM, et al. Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy. Oncologist. 2016 Dec;21(12):1416–e17.
   PubMed Web of Science ®Google Scholar
• Burtness BA, Manola J, Axelrod R, et al. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 May;19(5):977–983.
   PubMed Web of Science ®Google Scholar
• Sukari A, Al-Hajeili M, Salem M, et al. Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck. Avicenna J Med. 2015 Apr;5(2):36–41.
   PubMedGoogle Scholar
• Labourey JL, Cupissol D, Calais G, et al. Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol. 2007 Jun;30(3):278–282.
   PubMed Web of Science ®Google Scholar
• Malhotra B, Moon J, Kucuk O, et al. Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: southwest oncology group study S0329. Head Neck. 2014 Dec;36(12):1712–1717.
   PubMed Web of Science ®Google Scholar
• Kafri Z, Heilbrun LK, Sukari A, et al. Phase II study of gemcitabine and docetaxel combination in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck. ISRN Oncol. 2012;2012:159568.
   PubMedGoogle Scholar
• Argiris A, Buchanan A, Brockstein B, et al. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer. 2009 Oct 1;115(19):4504–4513.
   PubMed Web of Science ®Google Scholar
• Ho AL, Lipson BL, Sherman EJ, et al. A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer. Invest New Drugs. 2014 Jun;32(3):549–554.
   PubMed Web of Science ®Google Scholar
• Tsao A, Hui EP, Juergens R, et al. Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. Cancer Med. 2013 Jun;2(3):351–359.
   PubMed Web of Science ®Google Scholar
• Huang YC, Chang PM, Chen MH, et al. A study using ifosfamide and etoposide in patients with cisplatin-refractory recurrent or metastatic head and neck squamous cell carcinoma. Jpn J Clin Oncol. 2011 May;41(5):630–636.
   PubMed Web of Science ®Google Scholar
• Fury MG, Haque S, Stambuk H, et al. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. Cancer. 2011 Feb 15;117(4):795–801.
   PubMed Web of Science ®Google Scholar
• Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer. 2010 Jun 8;102(12):1687–1691.
   PubMed Web of Science ®Google Scholar
• Specenier P, Rasschaert M, Vroman P, et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2011 Oct;34(5):472–477.
   PubMed Web of Science ®Google Scholar
• Cho BC, Keum KC, Shin SJ, et al. Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2009 Dec;65(1):27–32.
   PubMed Web of Science ®Google Scholar
• Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005 Aug 20;23(24):5568–5577.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005 Aug 20;23(24):5578–5587.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007 Jun 1;25(16):2171–2177.
   PubMed Web of Science ®Google Scholar
• Fury MG, Sherman E, Lisa D, et al. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2012 Nov 1;10(11):1391–1398.
   PubMed Web of Science ®Google Scholar
• Rischin D, Spigel DR, Adkins D, et al. PRISM: phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck. 2016 Apr;38(Suppl 1):E1756–E1761.
   PubMedGoogle Scholar
• Seiwert TY, Fayette J, Cupissol D, et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2014 Sep;25(9):1813–1820.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May;16(5):583–594.
   PubMed Web of Science ®Google Scholar
• Clement PM, Gauler T, Machiels JP, et al. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol. 2016 Aug;27(8):1585–1593.
   PubMed Web of Science ®Google Scholar
• Fayette J, Wirth L, Oprean C, et al. Randomized phase ii study of duligotuzumab (MEHD7945A) vs cetuximab in squamous cell carcinoma of the head and neck (MEHGAN Study). Front Oncol. 2016;6:232.
   PubMed Web of Science ®Google Scholar
• Gilbert J, Schell MJ, Zhao X, et al. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2015 Apr;51(4):376–382.
   PubMed Web of Science ®Google Scholar
• Ruzsa A, Sen M, Evans M, et al. Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naive patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Invest New Drugs. 2014 Dec;32(6):1278–1284.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011 Apr;12(4):333–343.
   PubMed Web of Science ®Google Scholar
• Saloura V, Cohen EE, Licitra L, et al. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2014 Jun;73(6):1227–1239.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kwon HJ, Jung I, et al. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Clin Cancer Res. 2015 Feb 1;21(3):544–552.
   PubMed Web of Science ®Google Scholar
• Argiris A, Kotsakis AP, Hoang T, et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013 Jan;24(1):220–225.
   PubMed Web of Science ®Google Scholar
• De Souza JA, Davis DW, Zhang Y, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15;18(8):2336–2343.
   PubMed Web of Science ®Google Scholar
• Michel L, Ley J, Wildes TM, et al. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2016;58:41–48.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Specenier P, Krauss J, et al. A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2015 Jul;76(1):13–20.
   PubMed Web of Science ®Google Scholar
• Bauman JE, Arias-Pulido H, Lee SJ, et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol. 2013 May;49(5):461–467.
   PubMed Web of Science ®Google Scholar
• Massarelli E, Lin H, Ginsberg LE, et al. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015 Jul;26(7):1476–1480.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15;21(10):1980–1987.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 1;11(23):8418–8424.
   PubMed Web of Science ®Google Scholar
• Kirby AM, A’Hern RP, D’Ambrosio C, et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer. 2006 Mar 13;94(5):631–636.
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004 Jan 1;22(1):77–85.
   PubMed Web of Science ®Google Scholar
• Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009 Apr 10;27(11):1864–1871.
   PubMed Web of Science ®Google Scholar
• Perez CA, Song H, Raez LE, et al. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep;48(9):887–892.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar;10(3):247–257.
   PubMed Web of Science ®Google Scholar
• Grunwald V, Keilholz U, Boehm A, et al. TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). Ann Oncol. 2015 Mar;26(3):561–567.
   PubMed Web of Science ®Google Scholar
• Brooks HD, Glisson BS, Bekele BN, et al. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. 2011 May 15;117(10):2112–2119.
   PubMed Web of Science ®Google Scholar
• Fury MG, Baxi S, Shen R, et al. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res. 2011 Jan;31(1):249–253.
   PubMed Web of Science ®Google Scholar
• Schmitz S, Kaminsky-Forrett MC, Henry S, et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol. 2012 Aug;23(8):2153–2161.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Henry S, Zanetta S, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol. 2010 Jan 1;28(1):21–28.
   PubMed Web of Science ®Google Scholar
• Hanrahan EO, Kies MS, Glisson BS, et al. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2009 Jun;32(3):274–279.
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol. 2010 Mar;65(4):649–660.
   PubMed Web of Science ®Google Scholar
• Argiris A, Cohen E, Karrison T, et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006 Jul;5(7):766–770.
   PubMed Web of Science ®Google Scholar
• Geiger JL, Bauman JE, Gibson MK, et al. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Head Neck. 2016 Dec;38(12):1759–1764.
   PubMed Web of Science ®Google Scholar
• Choong NW, Kozloff M, Taber D, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct;28(5):677–683.
   PubMed Web of Science ®Google Scholar
• Swiecicki PL, Zhao L, Belile E, et al. A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer. Invest New Drugs. 2015 Dec;33(6):1248–1256.
   PubMed Web of Science ®Google Scholar
• Lalami Y, Garcia C, Flamen P, et al. Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer. Head Neck. 2016 Mar;38(3):347–354.
   PubMed Web of Science ®Google Scholar
• Jimeno A, Posner MR, Wirth LJ, et al. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2016 Dec 1;122(23):3641–3649.
   PubMed Web of Science ®Google Scholar
• Argiris A, Ghebremichael M, Gilbert J, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2013 Apr 10;31(11):1405–1414.
   PubMed Web of Science ®Google Scholar
• Limaye S, Riley S, Zhao S, et al. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral Oncol. 2013 Aug;49(8):835–841.
   PubMed Web of Science ®Google Scholar
• Knoedler M, Gauler TC, Gruenwald V, et al. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology. 2013;84(5):284–289.
   PubMed Web of Science ®Google Scholar
• Tinhofer I, Klinghammer K, Weichert W, et al. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res. 2011 Aug 1;17(15):5197–5204.
   PubMed Web of Science ®Google Scholar
• Massa E, Dessi M, Gaspardini G, et al. Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens. Oral Oncol. 2010 Nov;46(11):818–821.
   PubMed Web of Science ®Google Scholar
• Soulieres D, Faivre S, Mesia R, et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017 Mar;18(3):323–335.
   PubMed Web of Science ®Google Scholar
• Jimeno A, Bauman JE, Weissman C, et al. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral Oncol. 2015 Apr;51(4):383–388.
   PubMed Web of Science ®Google Scholar
• Jimeno A, Shirai K, Choi M, et al. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Ann Oncol. 2015 Mar;26(3):556–561.
   PubMed Web of Science ®Google Scholar
• Gilbert J, Lee JW, Argiris A, et al. Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern cooperative oncology group. Head Neck. 2013 Jul;35(7):942–948.
   PubMed Web of Science ®Google Scholar
• Chung CH, Aulino J, Muldowney NJ, et al. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2010 Apr;21(4):864–870.
   PubMed Web of Science ®Google Scholar
• Swiecicki PL, Bellile E, Sacco AG, et al. A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Invest New Drugs. 2016 Aug;34(4):481–489.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02741570 accessed 2018 Apr 26
   Google Scholar
• Seiwert TY, Weiss J, Baxi SS, et al. A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL. J Clin Oncol. 2016;34(suppl):Abstr TPS 6101.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02551159 accessed 2018 Apr 26. 2017.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02358031 accessed 2018 Apr 26
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03358472 accessed 2018 Apr 26
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT01856478 accessed 2018 Apr 26
   Google Scholar